Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V503 (9vHPV) Vaccine in Chinese Males
NCT05285826Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2022
- Primary completion
- May 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co.. Started Feb 2022; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05285826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285826.